Which drug type does entrectinib belong to and its specific mechanism of action?

Entrectinib (Entrectinib) is an oral small molecule multi-target tyrosine kinase inhibitor specifically designed to target the tumor growth mechanism caused by gene fusion. It is a representative of "tissue non-specific" targeted drugs. This type of drug does not only target cancers derived from a certain tissue, but specifically inhibits kinases that are abnormally activated due to specific gene fusions (such as NTRK1/2/3, ROS1 or ALK), thereby achieving broad-spectrum therapeutic effects in multiple types of tumors. Its main therapeutic mechanism is to block key downstream signaling pathways, such as MAPK and PI3K-AKT pathways, by binding to the ATP binding sites of TRKA/B/C, ROS1 and ALK proteins, ultimately inhibiting the growth, migration and spread of cancer cells.

The reason why entrectinib is called a "pan-tumor therapeutic drug" is because its therapeutic effect does not depend on the location of the tumor, but on whether there is a specific gene fusion in the tumor. Especially in NTRK fusion-positive patients, this gene rearrangement is often the core factor driving cancer progression, and inhibiting its activity is equivalent to cutting off the main energy supply pathway of cancer cells. It is worth mentioning that entrectinib has strong penetration into the central nervous system, so it has obvious advantages in treating patients with brain metastases. It can control intracranial lesions more effectively than traditional TKI drugs, which is a highlight in clinical research.

From the perspective of pharmacological properties, entrectinib is fundamentally different from traditional cancer treatments. Traditional therapies are often divided according to the anatomical location of tumors (such as lung cancer, gastric cancer, etc.), while entrectinib directly acts on the mechanism of cancer (non-small cell lung cancer) itself, making it effective in tumors of various origins.

Reference materials:https://www.roche.com/products/rozlytrek